AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 16, 2026, 5:09 AM ET Roth Capital raised its Capricor price target to $10.50 from $7 with a Neutral rating, while Oppenheimer kept Outperform and a $54 target ahead of the November 22 Deramiocel FDA decision. AI-generated summary · Source: press report
Nasdaq: $CAPRDeramiocel · Duchenne muscular dystrophyRefined upper-limb indicationBinary regulatory risk

CAPR Stock Hub: Capricor Therapeutics News, Deramiocel and FDA Review

Capricor’s deramiocel application has a November 22, 2026 FDA target action date following a major amendment. The refined proposed indication focuses on upper limb function, distinct from the cardiomyopathy question on which an advisory committee voted 9–3 against effectiveness in July. Statistical interpretation, open-label evidence and the final label remain central uncertainties. On November 10, 2026 the company reported about $198.5 million in cash, restricted cash and marketable securities at September 30, 2026, against $96.4 million nine-month operating cash use, and disclosed a Form 483 with one observation from the FDA’s July clinical-trial inspection.

Last updated: November 11, 2026Financial period: September 30, 2026Currency: USD
Research Library
The complete CAPR research report
74 pages · Research updated November 10, 2026 · Dated snapshot
Get the report (PDF)
FDA target action date · company disclosure
Deramiocel FDA review · November 22, 2026

The August 24 disclosure says the major amendment contains 24-month HOPE-3 open-label extension data and additional analyses supporting a refined upper-limb indication. A target date is not an assurance of approval, a particular label or an on-time outcome. Company announcement filed with SEC →

Latest company update: on November 10, 2026, after the market close, Capricor reported third-quarter results and held its conference call and webcast at 4:30 p.m. ET. The release confirms the November 22 target action date and states that the FDA’s July 2026 Bioresearch Monitoring inspection ended with a Form 483 containing one observation; the company has submitted its response and is awaiting FDA feedback (results release filed with SEC). Follow official FDA and company disclosures; the July advisory vote concerned effectiveness in DMD cardiomyopathy and was non-binding.

CAPR daily chart

CAPR daily stock chart from Finviz
Daily chart $CAPR. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts → · Finviz chart (affiliate)

CAPR stock: dated key data

Chart analysis · JC
Technical chart analysis of $CAPR with bull and bear scenarios on JC Just Charts.
Cash and securities
$198.5M
September 30, 2026; cash, cash equivalents, restricted cash and marketable securities.
Q3 net loss
$42.7M
Quarter ended September 30, 2026; $0.73 per share.
9M operating cash use
$96.4M
Nine months ended September 30, 2026; $96.428M in the filing.
Common shares
58.142M
58,142,114 outstanding at November 9, 2026.
Advisory committee vote
3–9–0
July 29, 2026; for/against/abstain on effectiveness in DMD cardiomyopathy. Non-binding.
Short interest
18.765M
October 30, 2026 settlement; 18,765,089 shares and 7.38 days to cover.

Financial and share data: September 30 Form 10-Q; dated price and short interest: Nasdaq historical prices and short interest.

Where Capricor stands now

The application’s proposed indication and evidentiary basis have evolved. The July advisory discussion centered on cardiomyopathy, while the major amendment seeks a refined upper-limb indication. Company analyses and the FDA briefing use different statistical-plan interpretations, so the results should not be compressed into a single undisputed efficacy claim.

The company’s official investor calendar provides the October 7 PPMD webinar presentation on HOPE-3 extension data. The presentation supplies company context alongside the separately published FDA assessment. Official webinar page →

The third-quarter release of November 10, 2026 adds dated facts ahead of the decision. Total operating expenses were about $44.7 million in the quarter, against $26.3 million a year earlier, driven mainly by pre-commercial activities and manufacturing scale-up; the net loss was about $42.7 million, or $0.73 per share, and no revenue was recognized. A workforce reduction of about 10% of employees was implemented in the quarter. The company says the San Diego GMP facility is positioned to support an initial commercial launch if deramiocel is approved, has begun regulatory engagement in Europe and Japan, and expects the arbitration hearing with Nippon Shinyaku and NS Pharma to begin in mid-2027. Chief Executive Officer Linda Marbán said the company remains confident in the strength of its data; that is the company’s position, not an indication of the FDA’s decision. Q3 release →

Main risk: The FDA must decide whether the submitted evidence supports an approvable indication. A negative prior advisory vote, statistical restatement, absence of a concurrent placebo comparator in extension data and commercial-partner disputes remain separate risks.

Constructive case

The company’s upper-limb analysis and longer follow-up provide evidence for the amended submission. Acceptance of a sufficiently supported narrower indication could establish a development path, while the September 30 reserve of about $198.5 million, with no ATM sales in 2026 through November 10, provides a cushion. These are conditional possibilities, not approval predictions.

Cautious case

The FDA may interpret the statistical record differently or require further evidence. Open-label comparisons cannot replace a concurrent randomized comparison. A further regulatory setback would affect commercialization, spending, partner arrangements and the lease contingency, while third-quarter operating expenses had already risen to about $44.7 million.

CAPR stock news: six latest updates

Nov 16, 2026

Roth lifts Capricor price target to $10.50, Oppenheimer holds $54 ahead of FDA decision

Roth Capital raised its Capricor price target to $10.50 from $7 and kept a Neutral rating, assigning a 25% chance of Deramiocel approval by November 22. Oppenheimer maintained an Outperform rating and $54 price target. The FDA rejected Deramiocel in July 2025, and an advisory committee voted 9-3 against the evidence for DMD-related cardiomyopathy in July. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 15, 2026

Capricor's Deramiocel FDA decision for Duchenne upper limb impairment due Nov. 22

Capricor awaits an FDA decision on Nov. 22 for Deramiocel in upper limb impairment in Duchenne patients older than nine, after the review was extended from Aug. 22. The FDA issued a complete response letter in July 2025, and in July an advisory panel voted 9-3 against the evidence of effectiveness for Duchenne-related heart disease. Capricor says Hope-3 met its main goal and its San Diego facility is ready to support an initial launch. Not confirmed by a company release or filing at the time of writing; to be verified.

Nov 13, 2026

Roth Capital lifts Capricor price target to $10.50 from $7

Roth Capital raised its price target on Capricor Therapeutics to $10.50 from $7. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 11, 2026

Jones Trading raises Capricor rating from Hold, sets $25 target

Jones Trading upgraded its rating on Capricor Therapeutics from Hold. The bank set a price target of $25. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 10, 2026

Capricor says deramiocel BLA in final review as Nov. 22 FDA action date nears

On its third-quarter call, CEO Linda Marbán said the deramiocel Biologics License Application is in final review ahead of the FDA's Nov. 22 target action date. Capricor is preparing for launch and pursuing independent commercialization during an ongoing arbitration with NS Pharma. Its San Diego facility can support roughly 250 patients annually, with an expansion targeted for validation in the first half of 2027 to support 2,000–2,500 patients. Cash was about $198.5 million as of September 30. Reported by the press from an official company announcement; the primary document was not yet available in our sources at the time of writing.

Nov 10, 2026

Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Capricor reported a net loss of approximately $42.7 million, or $0.73 per share, for the third quarter of 2026, compared to approximately $24.6 million, or $0.54 per share, for the third quarter of 2025. Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million as of September 30, 2026. The BLA for Deramiocel for Duchenne muscular dystrophy has a PDUFA target action date of November 22, 2026.

CAPR stock catalysts: dated milestones

  • November 10, 2026 · Q3 results and conference call, 4:30 p.m. ETCompleted

    Results for the quarter ended September 30, 2026 were released after the market close and discussed on the conference call and webcast: about $198.5 million in cash, restricted cash and marketable securities, a $42.7 million quarterly net loss, the November 22 target date confirmed and a Form 483 response awaiting FDA feedback. Q3 release · Announcement of November 3.

  • November 22, 2026 · Deramiocel target action dateCompany-disclosed FDA target

    Review of the major amendment and refined proposed indication; neither approval nor timing is guaranteed.

  • First half of 2027 · Cleanroom expansion validationCompany target

    Validation of the second-floor cleanroom expansion at the San Diego facility is targeted for the first half of 2027, according to the November 10 release.

  • Mid-2027 · Arbitration hearing with Nippon Shinyaku and NS PharmaCompany expectation

    The company expects the arbitration hearing on the deramiocel distribution agreement to commence in mid-2027.

  • December 31, 2026 · Lease approval contingencyDisclosed contractual condition

    The September 30, 2026 Form 10-Q states that either party may terminate the new headquarters lease if FDA approval of deramiocel on terms acceptable to the company is not received on or before this date, and that the lease term will be reassessed if the contingency is not resolved by then. It is not a projected cash payment or an assumed approval date.

HOPE-3 evidence: keep the analyses distinct

Randomized trial

Upper-limb interpretation

Capricor reports a positive primary analysis. The FDA briefing evaluates earlier statistical-plan specifications differently. A company efficacy claim and a regulator’s assessment must remain separately attributed.

Cardiac secondary endpoint

Statistical restatement

The company restated the key LVEF endpoint from p=0.04 to p=0.09. Endpoints below a failed hierarchical test are not automatically protected against Type I error.

Open-label extension

Longer follow-up, different comparator

The delayed-start analysis compares patients with their own prior year. It does not provide a concurrent placebo-controlled comparison during the extension.

FDA briefing document · Company statistical update · Extension release.

CAPR cash, dilution and commercial obligations

The September 30, 2026 reserve of about $198.5M, including restricted cash, must be read alongside $96.4M nine-month operating cash use, total liabilities of about $120.6M (largely lease obligations for the new headquarters and manufacturing facility) and future development or launch costs. The August release replaced the earlier dated runway guidance with an at-least-twelve-month statement, which the November 10 release repeats; the company said it would give longer-term guidance after greater regulatory clarity, and that it sold no shares under its at-the-market program from January 1 through November 10, 2026.

Unused financing capacity, outstanding securities and equity-plan capacity are different from issued common shares. The filing also describes commercial-partner proceedings and an approval-related lease contingency. A regulatory outcome can therefore affect more than the clinical program.

Capricor Therapeutics deep dive: the full analysis

The chapters below go through the company in detail: the scenarios around the November 22, 2026 action date, the regulatory sequence, the HOPE-3 trial and the endpoint that was restated, the advisory committee, the September 30 balance sheet, the abandoned partner economics and the litigation, the dated catalyst map and the assessment. Every figure carries its date and its primary source. The same research is available as a downloadable PDF in the Research Library.

01 CAPR stock scenarios: the November 22 action date and the refined label

These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.

ScenarioWhat it assumesWhat would confirm itWhat would break it
BullThe narrowed indication is the point. The advisory committee voted on cardiomyopathy; the amendment asks for upper limb function, where, on Capricor’s analysis, the trial met its primary endpoint at p=0.029 with a 54 per cent slowing of decline, published in The Lancet, now supported by 24-month extension data in a disease with no therapy of this kind. The FDA accepted the amendment citing unmet need. Approval on or near November 22 unlocks an $80 million milestone, a priority review voucher and a 30 to 50 per cent revenue share.An approval announced by 8-K, the lease contingency satisfied, and the right-of-use asset — kept and remeasured in the third-quarter filing — staying on the balance sheet after December 31 rather than being derecognised.A second complete response letter, or an approval so narrow that the addressable population and the Nippon Shinyaku economics both shrink.
BaseThe agency weighs an application whose key secondary endpoint has been restated into non-significance, whose hierarchy collapsed below it, whose advisory committee voted nine to three against, and which has already received one complete response letter for failing the substantial-evidence standard. The agency’s own reviewers wrote before the meeting that, on the plan they treat as pre-specified, the primary endpoint was not met and benefit-risk “appears unfavorable”. In this frame the outcome is another refusal or a further delay; the company’s own risk factors say the negative vote is expected to have a significant impact on approvability for cardiomyopathy.A complete response letter, or a further extension, with the company restating a path forward around the open-label extension and the upper limb endpoint.Approval on November 22, which would mean the agency read the primary endpoint and the unmet need as sufficient on their own.
BearA company with no product revenue, no approved product, one FDA refusal and one negative advisory committee vote behind it, a lawsuit against its own commercial partner, a patent suit from Mesoblast seeking an injunction, six securities and derivative actions, and a roughly $157 million lease commitment whose accounting has already had to be moved once, from an August to a November commencement estimate.A second complete response letter followed by lease derecognition, a withdrawn or lost arbitration against Nippon Shinyaku, or an adverse ruling in the Mesoblast case.Approval, a resolved partner dispute, and the 24-month data proving durable enough to carry a label.

What makes this case unusual is that the clinical question and the commercial question are both open at once. Even an approval leaves Capricor in litigation with the partner that holds exclusive United States distribution rights, and facing a patent claim that seeks to stop the product being made or sold.

What would falsify this reading

The reading in this report is that the November 22 date is a third attempt on a narrowed indication, that the cardiac endpoint no longer supports the application, that the advisory committee vote matters more than its non-binding status suggests, and that the commercial path is encumbered by litigation even if the drug is approved. Each of the following would damage that reading, and each is checkable against a document.

  • The primary endpoint turns out to be enough. On Capricor’s analysis HOPE-3 met it: 54 per cent slowing of upper limb decline, a least-squares mean difference of 4.55 percentage points, about 1.2 points absolute on the Performance of the Upper Limb 2.0 scale, p=0.029, published in The Lancet. The FDA’s briefing document reads the same endpoint, on the earlier plan it treats as pre-specified, as 0.66 points with p=0.24. If the FDA approves on that plus the 24-month extension data, the advisory committee vote on a different indication will have been the wrong thing to watch.
  • The 24-month data are as good as the market read them. The shares rose 10.50 per cent on September 30, during the Hiroshima congress, and gave part of that move back by October 2. Capricor released the upper-limb figures on October 5, in a company release rather than an SEC filing; the shares fell 13.07 per cent that day and were about a third below their October 2 level by October 23, before recovering part of the decline by November 10. The analysis is open-label and within-group; whether the FDA reads its delayed-start and natural-history comparisons as supporting evidence is the open question, and the market’s first reaction was a fall.
  • The balance sheet proves sufficient. About $198.5 million of cash, restricted cash and marketable securities at September 30, 2026, no debt of any kind, and a current ratio of about 6.8 (Merlintrader calculation from the balance sheet) against nine-month operating cash use of $96.4 million; at June 30 the figures were $237.9 million, 7.35 and $60.7 million over the half. The quarterly report carries no going-concern qualification and no substantial-doubt language. If the company funds itself through a refusal and a resubmission without a dilutive raise, the financial risk here is smaller than the clinical one.
  • The lease contingency resolves cleanly. An approval by December 31, 2026 on terms acceptable to the company would satisfy the contingency and keep the roughly $76.3 million right-of-use asset on the balance sheet. The asset was first measured on the assumption that the contingency resolves on August 22, 2026; after that date moved, the third-quarter report updated the estimated commencement to November 22, 2026 and remeasured the lease, adding about $73,000 to the asset and the liability; without an approval by the year end, either party may terminate within five business days and the filing says the company would then reassess the lease term and remeasure or derecognise the asset and the liability.
  • The partner dispute resolves. Capricor is seeking to rescind its own United States distribution agreement; in the arbitration Nippon Shinyaku and NS Pharma have filed a breach-of-contract claim and Capricor has filed counterclaims, and the company now expects the hearing to begin in mid-2027. A settlement that fixes the pricing structure the company calls fundamentally flawed would remove the largest commercial obstacle. A loss would leave an approved product in the hands of a distributor the company has told a court it cannot work with.

None of these is a prediction. They are the observations that would make the rest of this report wrong, listed so that a reader can check them rather than take the reading on trust.

02 The regulatory sequence, date by date

This case cannot be read without the chronology, because almost every summary of it collapses three separate action dates into one.

DateEvent
April 21, 2015Orphan Drug designation granted.
July 5, 2017Rare Pediatric Disease designation granted for Duchenne muscular dystrophy.
January 29, 2018RMAT designation granted on HOPE-Duchenne data.
December 2018Voluntary hold on dosing after a serious adverse event of anaphylaxis in HOPE-2. The investigation suggested a possible allergy to something in the investigational product, including possibly an excipient. A pre-medication regimen was introduced and dosing resumed.
August 2, 2024Type B pre-BLA meeting. According to the FDA, it recommended that a future application for “treatment of patients with DMD” include HOPE-3 results and did not consider HOPE-2 and its extension sufficient for a broad indication.
December 31, 2024Original BLA 125842 submitted, on HOPE-2 and HOPE-2-OLE, for cardiomyopathy in DMD; accepted with priority review; goal date August 31, 2025. The submission triggers a $10.0 million milestone from Nippon Shinyaku.
Mid-2025Pre-licence inspection of the San Diego facility; Form 483 with several observations; responses later accepted in full.
June 18, 2025Randomised, double-blind period of HOPE-3 completed (the registry’s primary completion date).
July 9, 2025Complete response letter, disclosed on a Form 8-K of July 11. The FDA states the application “did not meet the statutory requirement for substantial evidence of effectiveness” and requests additional clinical data. In the agency’s later summary, HOPE-2 failed its pre-specified primary endpoint and every key secondary endpoint.
August 13, 2025Type A meeting. Capricor proposed making LVEF the primary endpoint of HOPE-3; the FDA disagreed because the study was already under way, and said LVEF could potentially be considered a key secondary endpoint.
September 26, 2025Statistical analysis plan 2.0 and protocol 9.0 submitted; the FDA says its comment was not solicited and no concurrence obtained.
November 24–25, 2025SAP 3.0 created by Capricor on November 24, not submitted to the FDA; database lock and unblinding of HOPE-3 the next day.
December 3, 2025HOPE-3 positive topline announced by the company.
December 29, 2025BLA resubmitted with HOPE-3.
January 13, 2026Incomplete Response Letter: the FDA deems the resubmission incomplete, citing missing documents including a complete clinical study report, all versions of the protocol and statistical analysis plan, and narrative summaries.
February 20, 2026Complete resubmission with the requested data and information.
March 10, 2026Capricor announces that the FDA has lifted the complete response letter and resumed review, in the company’s wording; the agency classifies the submission a Class 2 resubmission and sets a goal date of August 22, 2026. The company’s release adds: “At this time, the FDA has not identified any potential review issues in its response to the Company.”
May 12, 2026The company reports “a significant number of information requests from FDA to Capricor, all of which the Company has been able to address”, and says it expects labelling discussions to commence soon.
June 26, 2026An advisory committee meeting is announced for July 29.
July 27, 2026The FDA’s briefing document is public; Capricor responds the same day that the agency’s analyses rely on “an unsigned incomplete internal draft” of the analysis plan.
July 2026Bioresearch monitoring inspection; Form 483 with one observation on HOPE-3 trial conduct. Response submitted; feedback pending.
July 29, 2026HOPE-3 published in The Lancet.
July 29, 2026Meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (docket FDA-2026-N-6771): 3 yes, 9 no, 0 abstaining on whether the evidence provides substantial evidence of effectiveness in Duchenne cardiomyopathy.
August 13, 2026The LVEF statistical restatement is disclosed, with the quarterly results.
August 24, 2026PDUFA extended to November 22, 2026; submission classified a major amendment; refined indication focused on upper limb function.
September 29–October 3, 2026World Muscle Society congress, Hiroshima: a late-breaking HOPE-3 extension poster and a HOPE-3 oral presentation on October 3, which the company said together report outcomes through 24 months. On October 5 Capricor released the upper-limb results of the extension in a press release; no company release or filing has reported cardiac results through 24 months.
October 7, 2026Capricor–PPMD community webinar on the robustness analyses and the extension data; the presentation and webcast were later posted on the company’s IR calendar.
November 7, 2026HOPE-3 twelve-month cardiac results presented at the American Heart Association Scientific Sessions; Outstanding Research Award in Pediatric Cardiology, announced on November 9.
November 10, 2026Third-quarter results: BLA under review with the November 22 target date; refined indication described as upper limb impairment in patients “> 9 years old”; Form 483 response awaiting FDA feedback.

Outside the United States

“In parallel with our U.S. regulatory activities, we have initiated regulatory engagement in Europe and Japan, and are working with the relevant health authorities to determine the most appropriate regulatory pathway for Deramiocel in those regions.” That is the whole of it. No marketing authorisation application, no Japanese filing, and no agency interaction dates are disclosed in the annual report, the three 2026 quarterly reports or the 2026 exhibits; the November 10 release repeats that regulatory engagement in Europe and Japan has begun.

No post-marketing requirement, commitment or risk evaluation strategy is disclosed, necessarily, because nothing is approved.

03 HOPE-3, and the endpoint that was restated

HOPE-3 is the pivotal trial: NCT05126758, a Phase 3 randomised, double-blind, placebo-controlled study in two cohorts, each randomised one to one, with quadruple masking, at twenty United States sites. Actual enrolment 106, males aged ten and above, average age around fifteen, ambulatory and non-ambulatory, all on stable systemic glucocorticoids. The company reports that roughly 90 per cent were on cardiac medication at baseline and roughly 75 per cent had a clinical diagnosis of cardiomyopathy. Deramiocel 150 million cells or placebo every three months for twelve months. Start June 22, 2022; actual primary completion June 18, 2025; estimated study completion March 2027; status active, not recruiting; no results are posted on the registry, and a certification to delay results posting was first posted on December 17, 2025. According to the Lancet paper, 139 boys were screened and 106 randomised, 54 to deramiocel and 52 to placebo. ClinicalTrials.gov →

What was originally reported, in December 2025 and March 2026

EndpointSlowing of progression against placebop-value as first reported
Performance of the Upper Limb 2.0 total score — primary, n=10654 per centp=0.029
Left ventricular ejection fraction — key secondary, n=8391 per centp=0.041
Myocardial fibrosis by late gadolinium enhancementThree-segment treatment difference at twelve monthsp=0.022
Ejection fraction in patients with baseline cardiomyopathy+3.3 percentage pointsp=0.017
Global statistical test, composite of upper limb, ejection fraction and patient global impression—p=0.017
Duchenne Video Assessment, “eat 10 bites”About 83 per centp=0.018

On the strength of that table the company stated, in its annual report of March 17, 2026, that HOPE-3 “showed statistical significance in all type 1 error controlled secondary endpoints”. The releases of March 10, March 12, May 12 and June 26 carry the same substance in different words — “All Type I error-controlled secondary endpoints also achieved statistical significance” and “all other Type I error-controlled secondary endpoints”.

What changed, in the company’s own words, from the quarterly report filed August 14, 2026

“As part of our dialogue with the FDA regarding the HOPE-3 data, and in connection with the peer review process with The Lancet, the Company identified an update to the statistical model used in its analysis of left ventricular ejection fraction, the key secondary endpoint of the study. Under the revised model, LVEF yields a p=0.09 (1.8 percentage point treatment difference), compared to p=0.04 previously reported (2.4 percentage point treatment difference). In the pre-specified cardiomyopathy subgroup, the result is nominally significant at p=0.02 (2.8 percentage point treatment difference). Because the LVEF result did not meet the pre-specified significance threshold, endpoints tested subsequently in the pre-specified hierarchical testing sequence are no longer considered to be controlled for Type I error, and results for those endpoints are reported as nominal. The primary endpoint of HOPE-3 … was unaffected.”

The mechanics, from the August 13 results release: “Capricor identified an issue with the statistical model in the clinical study report and reverted to the statistical analysis plan in place prior to unblinding. The only endpoint affected was left ventricular ejection fraction… nothing else changed in the data or its analysis.”

The endpoint ledger as it now stands

StatusEndpoints
Met, with Type I error control — Capricor’s readingPerformance of the Upper Limb 2.0, the primary endpoint: 54 per cent slowing, least-squares mean difference 4.55 percentage points (95% CI 0.47 to 8.63), about 1.2 points of absolute change, p=0.029, from the analysis in Capricor’s clinical study report. The FDA reads the same endpoint as not met: 0.66 points, p=0.24 (see below).
MissedLeft ventricular ejection fraction, the key secondary: p=0.09, 1.8 percentage points.
Nominal only, no longer error-controlledEverything below ejection fraction in the hierarchy: the cardiomyopathy subgroup (2.8 percentage points, p=0.02, against +3.3 points and p=0.017 first reported), mid-level upper limb, the global statistical test, cardiac global statistical test, left ventricular end-systolic volume, late gadolinium enhancement and scar, CK-MB, and the video assessment.

Two practical consequences. The first is that the claim that the trial showed statistical significance in all Type I error-controlled secondary endpoints, which still circulates and still sits in at least five company documents published before August — the annual report of March 17 and the releases of March 10, March 12, May 12 and June 26 — is a superseded statement. The second is that the amendment’s pivot to upper limb function is not a presentational choice: on Capricor’s analysis, upper limb function is now the only claim the trial supports with full statistical control. On the FDA’s analysis, it supports none, which is why the next subsection matters more than any other in this report.

Two readings of the same trial

Everything above is Capricor’s account of HOPE-3. The FDA’s briefing document for the July 29 meeting reads the same trial differently, and because the November decision belongs to the agency rather than to the company, the two accounts have to be read side by side. The disagreement is not mainly about the data. It is about which statistical analysis plan governs them.

The FDA treats SAP 1.1, dated July 19, 2022 and prepared by the contract research organisation under the approved blinding plan, as the pre-specified plan. Under it the primary endpoint is the change in PUL 2.0 total score measured in points, and the agency’s analysis finds a difference of 0.66 points (95% CI −0.45 to 1.77), p=0.24. LVEF, the key secondary, shows a difference of −0.041 percentage points, p=0.97, and the documented cardiomyopathy subgroup (79 patients) shows 0.85 percentage points of LVEF, p=0.59. The document’s summary sentence is unambiguous: “The study did not meet its pre-specified primary and secondary efficacy endpoints.” It also records that SAP 2.0 (September 26, 2025) and SAP 3.0, dated November 24, 2025 — one day before database lock and unblinding on November 25 — were prepared by Capricor itself, that SAP 3.0 was not submitted to the FDA before the resubmission, and that the 4.55 percentage-point, p=0.029 result Capricor reports is not SAP 3.0 as written but the analysis in its clinical study report of February 3, 2026, which added a “slow progressor” term that, according to the FDA, should have been excluded under the sponsor’s own criteria; “the inclusion of this variable lowered the p value”. On SAP 3.0 as written, the agency computes 4.16 percentage points (95% CI 0.09 to 8.23), p=0.045; using SAP 1.1’s handling of missing data with SAP 3.0’s model, 2.53 percentage points, p=0.21.

The briefing document carries its own caveat, which applies to every reference to it in this report: its conclusions “do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office.” It is the reviewers’ analysis placed before the committee, not the agency’s decision.

Capricor’s answer came on July 27, 2026. It called SAP 1.1 “an unsigned incomplete internal draft which became obsolete with the addition of cohort B”, and said: “Our results are governed by the final analysis plan, SAP version 3.0, which was finalized prior to unblinding.” The Lancet paper reports the trial on SAP 3.0. Capricor, July 27, 2026 →

QuestionCapricor’s readingFDA briefing document
Governing analysis planSAP 3.0, dated November 24, 2025, “finalized prior to unblinding”SAP 1.1, dated July 19, 2022; SAP 3.0 written by the sponsor one day before unblinding and never submitted for FDA comment
Primary endpoint definitionPercent change from baseline in PUL 2.0 total scoreChange from baseline in PUL 2.0 total score, in points
Primary result, SAP 1.1 (FDA analysis)Plan not accepted as governing: “an unsigned incomplete internal draft”0.66 points, 95% CI −0.45 to 1.77, p=0.24
Primary result, SAP 3.0 as written (FDA analysis)Not the figure the company reports4.16 percentage points, 95% CI 0.09 to 8.23, p=0.045
Primary result, SAP 3.0 as modified in the clinical study report (Capricor analysis, February 3, 2026)4.55 percentage points, 95% CI 0.47 to 8.63, p=0.029 (about 1.2 points absolute); the figure in the company’s releases and the Lancet paperAdds a “slow progressor” term the FDA says should have been excluded and that lowered the p-value
LVEF, key secondary1.8 percentage points, p=0.09 after the August restatement−0.041 percentage points, p=0.97
Cardiomyopathy subgroup, LVEF2.8 percentage points, nominal p=0.020.85 percentage points, 79 patients, p=0.59
Overall verdictPrimary endpoint met and unaffected by the restatement“Did not meet its pre-specified primary and secondary efficacy endpoints”; benefit-risk “appears unfavorable”; no subgroup identified that may benefit

One detail ties the two accounts together. The p-value of the LVEF result Capricor restated in August, p=0.09, matches the column the FDA labels “SAP 3.0 with data imputation” — the p-value, not the estimate, since Capricor reports 1.8 percentage points and the FDA column a ranked change of 9.51. On that reading, which is a Merlintrader inference from the two documents, the “statistical analysis plan in place prior to unblinding” to which the company reverted is SAP 3.0, not the 2022 plan the agency relies on: the August restatement brought the cardiac analysis into line with SAP 3.0 as written, while the primary result the company reports remains the study-report version.

The agency raises two further points. It treats a change of at least one point on PUL 2.0 as clinically relevant, and notes that HOPE-3 was powered to detect 1.5 points: Capricor’s translation of its result is about 1.2 points, the FDA’s estimate is 0.66. And it flags a risk of functional unblinding, because hypersensitivity reactions were far more frequent on deramiocel than on placebo, so post-hoc plan changes “have a high risk of bias” even when formally made blind. FDA briefing document, BLA 125842 →

What the earlier trials showed

HOPE-2, NCT03406780, randomised, double-blind, placebo-controlled, roughly 90 per cent non-ambulant, published in The Lancet in 2022. In the company’s account it met its primary endpoint on the mid-level dimension of the upper limb scale at p=0.01, with the full version 2.0 scale at p=0.04, and reported 107 per cent slowing of cardiac decline at p=0.002 with significant benefits in indexed ventricular volumes. The FDA tells it differently: the trial was designed for 84 patients and enrolment was stopped at 20 after an interim analysis, the analysis plan was changed after the data were unblinded to the sponsor, and on the pre-specified model HOPE-2 failed its primary endpoint and every key secondary endpoint — the basis of the July 2025 complete response letter. Its open-label extension has since reported five-year data on the nine patients still enrolled, presented at the Parent Project Muscular Dystrophy conference on June 27, 2026; the company described a mean decline of less than five points on the upper limb scale over five years and cardiac function stable against external comparators. Capricor, June 26, 2026 → HOPE-Duchenne, twenty-five patients randomised one to one, a single intracoronary administration, published in Neurology in 2019: improvements in a defined post-hoc analysis of combined mid-distal upper limb subscales, with no significant difference in treatment-emergent adverse events between groups and no discontinuations for adverse events.

The safety that is not in the filings, and where it is

This needs saying plainly. Arm-level serious adverse event rates, discontinuation counts, deaths and specific signal frequencies for HOPE-3 are absent from the company’s SEC filings — the 2025 annual report, both 2026 quarterly reports, and the exhibits to all eleven 2026 Forms 8-K. The registry has no results section posted. The filings offer only qualitative statements: that deramiocel “maintained a safety and tolerability profile consistent with prior clinical experience” and that “the long-term safety profile is consistent and well characterized”. The only quantified safety events anywhere in the filings are the single HOPE-2 anaphylaxis event and the December 2018 dosing hold that followed it. Arm-level HOPE-3 safety is not in a filing, but it is public: in the Lancet paper, which reports no deaths and describes safety as similar to placebo, and in the FDA’s briefing document.

HOPE-3, randomised double-blind period (FDA briefing document)DeramiocelPlacebo
Safety population53 (one patient randomised to deramiocel withdrew consent before any dose)52
Any hypersensitivity reaction22 of 53, 41.5%8 of 52, 15.4%
Serious adverse events1 patient: a Grade 2 infusion-related reaction at the second infusion; treatment continued5 patients, including a Grade 4 anaphylactic reaction at the first infusion, possibly linked to excipients the placebo shared; that patient was discontinued
Full-infusion completion across the four dose visits84.9%–92.5%92.3%–94.2%

The FDA also notes one suspected case of “immune sensitization syndrome” on deramiocel, and that eleven placebo patients without hypersensitivity in the blinded period developed hypersensitivity reactions once they crossed over to open-label treatment. The pattern is the basis of the agency’s functional-unblinding concern described above. FDA briefing document, section 3.3 →

04 The advisory committee, and what a negative vote predicts

On July 29, 2026 the Cellular, Tissue and Gene Therapies Advisory Committee voted three yes, nine no, none abstaining on the question “Does the available evidence provide substantial evidence of effectiveness … for the treatment of cardiomyopathy in patients with DMD?” The meeting was held under docket FDA-2026-N-6771, on BLA 125842. FDA voting question → Three facts about that vote have to travel together or the reader is misled in one direction or the other.

It is non-binding. The FDA is not obliged to follow it and says so.

It was on a narrower question than the company asked. In Capricor’s words: “The Committee’s voting question addressed a narrower indication than Capricor had proposed and did not include a vote on Deramiocel’s overall benefit-risk profile.” There was a separate, non-voting discussion of upper limb function which the company describes as directionally supportive. The committee had in front of it an FDA briefing document concluding that HOPE-3 missed its pre-specified primary endpoint, that the agency could not identify a subpopulation likely to benefit, and that benefit-risk “appears unfavorable in the absence of evidence of effectiveness” — so the agency’s reviewers had stated their own view before the vote. FDA briefing document →

And the company itself does not treat it as cosmetic. From its own risk factors: the negative vote “is expected to have a significant impact on Deramiocel’s approvability in the U.S. for the treatment of cardiomyopathy in patients with DMD”, and the FDA “may give us a complete response letter (rejecting our amended BLA) or further delay approval”.

What the published record says about votes like this one

This is the part that is almost never quantified in coverage of an adverse advisory committee vote, and it is quantifiable.

A review of all 409 human drug advisory committee meetings held between 2010 and 2021 found that FDA regulatory actions aligned with 262 of 298 votes, 88 per cent. The asymmetry inside that figure is the interesting part: approval followed 142 of 147 positive votes on initial approvals, 97 per cent — but non-approval followed only 40 of 60 negative votes on initial approvals, 67 per cent. The authors note that discordance between the agency and its committees was most frequently an approval after a negative vote (Daval et al., JAMA Health Forum, 2023). An accompanying commentary made the same point about the asymmetry: the agency nearly always followed a committee that said “go” and departed from one that said “stop” about a third of the time (Kanter, JAMA Health Forum, 2023).

Two earlier analyses give the same shape with different numbers. A review of 376 voting meetings from 2008 to 2015 found 22 per cent of final actions discordant with the committee, of which 75 per cent were the agency being more restrictive than its advisers and 25 per cent less restrictive; discordance was associated with lower degrees of committee consensus (Zhang et al., The Milbank Quarterly, 2019). An analysis of 163 voting sessions from 2010 to 2015 found the agency’s decision in line with the committee in 90 per cent of cases, with disagreement most often driven by a different view of clinical importance (McCormack, JAPhA, 2018).

How that applies, and how it does not

Three qualifications matter before anyone treats “one in three” as a probability for this case.

First, the 67 per cent figure is not measured at the next action date: the authors assessed agency action one year after the vote and as of November 30, 2022, so part of the one-third discordance can be approval after a resubmission, which is a different event from approval on November 22. Both Daval and McCormack studied drug committees reviewed by the Center for Drug Evaluation and Research; the Cellular, Tissue and Gene Therapies committee advises the Center for Biologics Evaluation and Research, so this application probably sits outside both samples. Capricor has already been through one complete response letter and one resubmission, so it is already inside that pathway rather than at the start of it.

Second, the discordance literature finds disagreement more likely where committee consensus was weak. Nine to three is not a weak consensus. It is a clear majority against.

Third, and the only point that genuinely cuts the company’s way: the committee voted on cardiomyopathy, and the amendment now under review asks for upper limb function. A vote against effectiveness in one indication is not a vote against effectiveness in another, and the endpoint underlying the second claim is the one the trial met with full statistical control on Capricor’s analysis plan — though not on the plan the FDA’s reviewers treat as pre-specified. Whether the agency sees that as a different question or as the same application in different clothing is the whole of November 22, and no published base rate answers it.

These are peer-reviewed external references, not company disclosure. They are included to give the vote a scale, and they are not a prediction.

05 The balance sheet and the runway guidance

Capricor is a pre-revenue company with a genuinely unencumbered balance sheet and a guidance record that tells its own story. Both halves of that sentence matter, and the second half only exists in the press-release exhibits attached to the quarterly 8-Ks, not in the financial statements themselves.

The quarterly report for the period ended June 30, 2026 is presented in whole dollars, not thousands. That is unusual enough to generate errors in secondary coverage, so the figures below are given as filed.

Income statementQ2 2026Six months 2026
Revenue$0$0
Research and development$28,866,292$56,243,204
General and administrative$14,079,328$23,475,269
Total operating expenses$42,945,620$79,718,473
Net loss$(40,733,654)$(74,674,999)
Loss per share, basic and diluted$(0.70)$(1.29)

Revenue is exactly zero — for the quarter, for the half, for the comparable 2025 periods and for the whole of 2025. The $50 million of upfront and milestone money received from Nippon Shinyaku under the United States agreement was fully recognised as revenue by December 31, 2024, which is why nothing of it appears now. The $12.0 million sitting in current deferred revenue is the Japanese upfront, received in 2023, and it has been parked there unrecognised ever since because, in the company’s own words, it cannot identify any distinct performance obligation against it.

Balance sheet, June 30, 2026As filed
Cash and cash equivalents$20,935,187
Marketable securities$216,999,595
Cash, equivalents and marketable securities$237,934,782
Total assets$368,735,835
Total liabilities$122,516,945
  of which operating lease liabilities$91,045,362
  of which deferred revenue (Japan)$12,000,000
Total stockholders’ equity$246,218,890
Accumulated deficit$(379,553,484)
Cash used in operating activities, six months$(60,740,078)

Two details in that table deserve to be pulled out, because the headline number is routinely mis-stated in both directions. Cash on the balance sheet is $20.9 million. The $237.9 million figure quoted everywhere is cash plus marketable securities. Writing “$20.9 million of cash” without the securities understates the position badly; writing “$237.9 million of cash” overstates the liquid component. Both appear in circulation.

And the largest single liability on the sheet is not debt. Capricor has no borrowings of any kind. The one loan it carried — a California Institute for Regenerative Medicine award of approximately $3.4 million from 2016 that the company elected in February 2025 to convert from a revenue-sharing grant into a loan — was repaid in full during the first half of 2026, under a May 2026 repayment agreement, for approximately $6.3 million comprising about $3.4 million of principal and about $2.9 million of accrued interest. Converting it extinguished a royalty obligation that could have run to nine times the amount awarded. The $91.0 million of liabilities is the real-estate lease stack, and that is a separate problem treated in the next section.

No going-concern qualification, and a guidance line that was quietly withdrawn

There is no going-concern qualification and no substantial-doubt language anywhere in the quarterly report. The sufficiency statement reads that the company believes its cash, equivalents and marketable securities are “sufficient to fund our operating capital requirements for at least the next twelve months from the issuance date of these condensed consolidated financial statements.” The current ratio is 7.35.

What makes that statement worth reading carefully is what it replaced. The runway guidance was stated with a terminal date in two consecutive quarters and then dropped, and it only ever appeared in the press-release exhibits.

DateCashRunway guidance, as given
March 12, 2026~$318 millionSufficient “through 2027”
May 12, 2026~$279 millionSufficient “through Q4 2027”; the headline bullet reads “into Q4 2027” — the same terminal quarter as March, stated more precisely
August 13, 2026~$238 million“at least the next twelve months”, with longer-term guidance deferred “following greater regulatory clarity, which will inform future strategic and capital allocation decisions”
November 10, 2026~$199 million“at least the next twelve months” repeated; longer-term guidance again deferred until greater regulatory clarity, excluding product revenue, a priority review voucher and other non-operating capital

The guidance was not dropped because the cash ran short. On the half-year operating burn of $60.7 million, $237.9 million is roughly two years of operations at the current rate without a single dollar raised. That is the operating figure. Adding the $16.6 million spent on property, equipment, leasehold improvements and construction in progress in the half, and the $6.3 million one-off CIRM repayment, gives an all-in outflow of about $83.7 million, or about $80.2 million net of $3.6 million of option-exercise proceeds — roughly a year and a half of cover at that pace (Merlintrader calculation from the cash-flow statement). In Merlintrader’s reading, a company with that cover would not normally replace a dated runway statement with a generic twelve-month floor. The August language is a statement about regulatory uncertainty, not liquidity — and the same exhibit says in terms that commercial readiness is advancing “at a slower pace” and that programmes unrelated to deramiocel are on hold. In Merlintrader’s reading, the withdrawal of the date is the clearest single signal of how the company itself reads its odds.

The qualifying language that follows the sufficiency statement is standard but specific: estimates are “based on assumptions that may prove to be wrong,” the company “may need to obtain additional funds sooner than planned or in greater amounts,” equity issuance would mean stockholders “may experience significant dilution,” and — the operative sentence — “the timing and scale of any commercial launch expenditures, and our ability to access capital on favorable terms, may be affected by the outcome of the FDA’s review of the BLA.”

Note also what is absent. The annual report of March 17 guided 2026 spending of $100 million to $125 million on the deramiocel programme and $7 million to $10 million on exosomes; the second-quarter report repeats neither range. Form 10-K, 2025 → There is now no revenue, expense, earnings or margin guidance of any kind, and no valuation is placed on the priority review voucher the company expects to receive on approval, despite the voucher being referenced repeatedly as a potential source of non-operating capital.

Third-quarter 2026 results

The quarterly report for the period ended September 30, 2026, filed on November 10, shows revenue of zero for the quarter and the nine months. Research and development expenses were $29,558,388 and general and administrative expenses $15,124,348, for total operating expenses of $44,682,736 against $26,284,040 a year earlier; the net loss was $42,656,101, or $0.73 a share, against $24,570,647. Over nine months the net loss was about $117.3 million, or $2.03 a share, and net cash used in operating activities was $96,428,210. The company attributes the increase mainly to pre-commercial activities and manufacturing scale-up, and implemented a workforce reduction of about 10 per cent of employees in September, with about $579,000 of one-time termination benefits.

At September 30, 2026 cash and cash equivalents were $44,279,993, marketable securities $153,300,986 and restricted cash about $958,000 — about $198.5 million in all, against $237.9 million at June 30. Total assets were $330,370,421, total liabilities $120,605,812, of which $92,229,961 operating lease liabilities, and stockholders’ equity about $209.8 million. The current ratio is about 6.8 (Merlintrader calculation). The release repeats that resources are sufficient for at least the next twelve months and that no shares were sold under the at-the-market programme from January 1 through November 10, 2026. In Merlintrader’s reading, quarterly operating spending of $44.7 million, against a nine-month operating cash use of $96.4 million, is the figure to set against the twelve-month statement, since launch costs would come on top. (Form 10-Q, quarter ended September 30, 2026; results release, November 10, 2026)

06 The partner: the economics lost and the lawsuit to rescind

Capricor does not own its United States commercial channel. It signed it away in January 2022, and in May 2026 it went to court to get it back. This is the part of the story that has no equivalent at most companies facing an approval decision, and it is the reason an approval in November would not automatically be a commercial event.

What the agreements actually pay

AgreementEconomics to CapricorStatus
United States, dated January 24, 2022$30.0m upfront (received); $10m on the HOPE-3 futility analysis (received); $10m on BLA submission, triggered December 2024 (received); $80.0m on receipt of marketing approval; up to $605.0m of sales-based milestones; revenue share “between 30 and 50 percent”Capricor is suing to rescind it
Japan, dated February 10, 2023$12.0m upfront (received 2023, still deferred); up to approximately $89.0m of development and sales milestones, subject to exchange rates; “a meaningful double-digit share of product revenue”In force
Europe, binding term sheet signed September 16, 2024$20.0m on execution of a definitive agreement; milestones up to $715.0m; double-digit revenue shareExpired April 1, 2026 and was not extended

The European line is worth pausing on, because it was disclosed without a press release and without an 8-K. The quarterly report states that “the amended term sheet with Nippon Shinyaku with respect to the treatment of DMD in Europe expired on April 1, 2026, and was not further extended.” No definitive agreement was ever executed, and nothing was ever recorded on the balance sheet, so nothing had to be written off. Up to $735 million of contingent European economics simply ceased to exist in a sentence inside a note. Whatever it signals about the relationship between the two companies, it happened five weeks before Capricor sued.

The lawsuit, and the mechanism it describes

On May 7, 2026 Capricor filed a verified complaint for equitable relief, plus an application for a preliminary injunction, in the Superior Court of New Jersey, Chancery Division, Bergen County, against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. Skadden, Arps acted; the verification was signed by chief financial officer A.J. Bergmann. The full 42-page complaint was filed as Exhibit 99.2 to the 8-K, which makes it the most detailed document the company has put on the record all year and the one least likely to be read.

The core allegation is not a commercial disagreement but a pricing mechanism the company says cannot work: “the parties’ mutual mistake was that the interaction between the Distribution Agreement’s pricing formula and the federal Medicare reimbursement framework ensures that, in a very short time, neither party can afford to manufacture, distribute, sell, or administer Deramiocel to patients covered by Medicare” — with spillover alleged into Medicaid and private insurance. Deramiocel is an intravenous cell therapy administered quarterly, which places it in a reimbursement category where the formula matters far more than it would for a dispensed drug.

Alongside that, the complaint alleges failures to prepare for launch that are specific enough to be checkable if the matter is ever tried: that NS “did not complete an acceptable gross-to-net revenue model,” “has not established a realistic wholesale price,” “has not conducted a single mock launch exercise,” entered into “subdistribution agreements with third parties… without Capricor’s written consent,” was “redirecting its commercial personnel to market and sell its Viltepso product rather than maintaining a dedicated Deramiocel team,” and failed to establish minimum sales requirements.

The repudiation narrative carries dates. On March 27, 2026 Nippon Shinyaku’s chief executive Toru Nakai met Capricor’s chief executive Linda Marbán and said a particular structure — redacted in the public filing — was required for United States distribution; on April 1, 2026 Marbán wrote to NS Pharma’s vice president of business development, Mr Kimura, confirming her understanding of that position, and he replied the same day. The complaint says Capricor raised the distributor’s deficiencies “no later than March 2025”, and that the distributor “has either failed to respond satisfactorily or has affirmatively disclaimed its obligations”, citing an email from NS Pharma’s general counsel of November 6, 2025.

Eight counts are pleaded: rescission for mutual mistake, rescission for unilateral mistake, rescission for frustration of purpose, declaratory judgment that Capricor may distribute the product itself or through others, breach of contract, anticipatory repudiation, breach of the implied covenant of good faith and fair dealing, and unjust enrichment. The relief sought includes rescission, an injunction barring NS from holding itself out as exclusive United States distributor, and restitution and disgorgement.

The procedural turn most summaries miss

Verbatim from the quarterly report: “The state court was scheduled to hear Capricor’s motion for preliminary injunction on August 10, 2026, ahead of the current PDUFA action date. Capricor withdrew the motion, without prejudice, having determined that resolving this contractual dispute in arbitration following the FDA’s decision would give the parties a more complete regulatory record to work from.” And, separately: “In addition, NS has asserted counterclaims against us.”

So the injunction that would have settled the distribution question before an approval was pulled, the venue moved to arbitration that the company expected to begin “this fall,” and the nature and amount of the counterclaims were not disclosed in the August filing. The quarterly report for the period ended September 30, 2026 states that arbitration proceedings have commenced: NS filed a complaint for breach of contract seeking declaratory and injunctive relief holding that Capricor breached the distribution agreement, that the agreement remains in full force and effect, and requiring Capricor to perform; Capricor filed counterclaims for breach of contract, breach of the implied covenant of good faith and fair dealing, rescission based on mutual mistake, a declaration of its right to distribute deramiocel and unjust enrichment, seeking damages and, alternatively, restitution. No amount is disclosed. The November 10 release says the company expects the arbitration hearing to commence in mid-2027. The certification attached to the May complaint had stated that the matter was not then the subject of any arbitration; by August it was heading there. Nippon Shinyaku’s own position, stated on May 8, is that “Capricor’s claims lack merit”, while it remains “open to discussions with Capricor to maximize the value of CAP-1002 (deramiocel).” Nippon Shinyaku, May 8, 2026 → Capricor’s stated position has not softened: it “continues to believe the pricing structure in the U.S. Distribution Agreement is fundamentally flawed in a way that would impede patient access, and continues to seek rescission.”

The practical shape of that for a reader: if the FDA approves in November, an $80 million approval milestone becomes payable to Capricor by the same counterparty it is trying to remove, and the product’s route to patients runs through a distributor the company has told a court cannot price it viably. Nippon Shinyaku also holds 4,944,429 shares, about 8.5 per cent of those outstanding, plus 2,145,922 warrants — about 12 per cent, both as of the February 28, 2026 proxy with the warrants counted — and is formally a related party. Neither side has outstanding receivables or payables with the other.

What Capricor owes others on approval

Two obligations sit on the other side of the ledger and are small but datable. Capricor paid Johns Hopkins University a $500,000 development milestone in April 2026 relating to the Phase 3 study, and the filing states that the “next and final development milestone” of $1,000,000 will be triggered, if at all, upon receipt of full FDA market approval, against maximum aggregate milestones of $1,850,000 and a low single-digit running royalty. Cedars-Sinai holds the foundational deramiocel and exosome licences at low single-digit royalties plus a share of sublicence consideration.

07 CAPR stock catalysts: the dated map

Dated events first, then the things that have a window rather than a date. Everything here is sourced to a filing or a company release; nothing is a forecast of outcome.

DateEventWhy it matters
November 10, 2026 · completedThird-quarter reportReleased after the market close with the Form 10-Q: about $198.5 million of cash, restricted cash and marketable securities, a $42.7 million quarterly net loss, no at-the-market sales in 2026, the lease remeasured to a November 22 commencement estimate, the Form 483 response still awaiting FDA feedback, and longer-term guidance again deferred “following greater regulatory clarity.”
November 22, 2026PDUFA target action date on the BLA as amended — refined indication focused on upper limb impairment in patients “> 9 years old”Confirmed in the November 10 release. The third action date on this application, and a Sunday, so any action may come on or before it. An approval makes an $80 million milestone payable by Nippon Shinyaku — under the same agreement Capricor is suing to rescind, so its practical collection is bound up with the arbitration — triggers a $1 million final milestone owed to Johns Hopkins, and brings priority-review-voucher eligibility. A refusal re-opens the question of what else the file can support.
December 31, 2026Lease contingency deadlineIf there is no FDA approval on terms acceptable to the company in its sole discretion by this date, either party may terminate the headquarters lease within five business days. A $76.3 million right-of-use asset and a $75.5 million liability were recognised on the assumption that the contingency resolves; the third-quarter report remeasured the lease to a November 22, 2026 commencement estimate and says the lease term will be reassessed if the contingency is not resolved by December 31.
First half of 2027StealthX Phase 1 final results, subject to finalisation by NIAIDMoved from “later in 2026” in the third-quarter report, after an earlier slip from the second quarter of 2026. Preliminary data showed limited neutralising antibody responses. Programmes not related to deramiocel have been slowed.
First half of 2027Validation of the second-floor cleanroom expansion at the San Diego facilityCompany target in the November 10 release. The May 12 results release gave a capacity target of 2,000–2,500 patients a year, roughly 10,000 doses; the August release had said “full validation and FDA inspection in 2027, as planned”.
Mid-2027Arbitration hearing with Nippon Shinyaku and NS Pharma expected to commenceCompany expectation in the November 10 release; in August the company had expected the arbitration to begin “this fall”. NS claims breach of contract and seeks to keep the distribution agreement in force; Capricor counterclaims and seeks rescission. No amounts are disclosed.

Undated but live

  • Publication or filing of the 24-month HOPE-3 extension data. Presented at the 31st World Muscle Society Congress in Hiroshima, which closed on October 3, 2026. The September 17 announcement does not supply effect sizes, confidence intervals, p-values or a safety table; the October 5 release reported the upper-limb figures, and no company release or filing had reported the 24-month cardiac figures or a safety table by November 10; the November 9 release covers twelve-month randomised cardiac results.
  • FDA feedback on the July 2026 bioresearch monitoring Form 483. One observation on HOPE-3 conduct; response submitted; feedback pending as of November 10.
  • Any development in the Mesoblast patent action in the District of Delaware, where injunctive relief is sought against a product awaiting approval.
  • A capital raise. Roughly $47.5 million of at-the-market capacity sits unused under the September 2025 programme, whose maximum was cut from $150.0 million to $125.0 million in December 2025, . Nothing had been sold under it from January 1 through November 10, 2026. The mechanism is in place and requires no further authorisation; a materially larger raise would need a new registration.
  • Any European partnering. The Nippon Shinyaku term sheet worth up to $735 million of contingent economics expired on April 1, 2026 and was not extended. Europe is currently unpartnered.
  • Trial initiations in younger Duchenne patients and Becker muscular dystrophy, explicitly stage-gated to the United States regulatory pathway.

One absence belonged on this map. No Capricor-originated filing of any kind appeared on EDGAR between August 24, 2026 and November 10, 2026 — about eleven weeks of the run-up to the action date, during which the only new documents on the company’s EDGAR page before the results were third-party Schedule 13G filings from Millennium on September 14 and October 14. After them came two amendments, on November 13 and November 16, in which Tang Capital and the Montanova and Averill group each reported no position at September 30, 2026. The gap closed with the third-quarter Form 8-K and Form 10-Q of November 10.

08 The bottom line on CAPR

Capricor arrives at November 22, 2026 with a drug that met its primary endpoint on its own analysis and missed it on the plan the FDA’s reviewers treat as pre-specified, an application that has already been refused once, an advisory committee that voted nine to three against effectiveness, a key secondary endpoint that was restated into failure, an indication that has been narrowed after the vote, and a headquarters lease either side may terminate if the approval does not come by December 31.

The positive case is real and does not require charity. On Capricor’s analysis — SAP 3.0 as applied in its clinical study report — HOPE-3 met its primary endpoint, was published in The Lancet, and in the company’s account was unaffected by the statistical restatement: a 54 per cent slowing of upper limb decline, a least-squares mean difference of 4.55 percentage points, p=0.029, in a population averaging fifteen years of age and already on steroids. The arithmetic is consistent with the published natural history of the disease. The need is as unmet as any in neurology, and since November 2025 the only approved gene therapy in Duchenne has carried a boxed warning for acute liver failure and has not been indicated for non-ambulatory patients at all — leaving steroids and givinostat, neither indicated for the cardiac involvement most of the HOPE-3 population carried. The balance sheet is clean: about $198.5 million of cash, restricted cash and marketable securities at September 30, 2026, no borrowings of any kind, a current ratio of about 6.8 (Merlintrader calculation), no going-concern qualification in the quarterly report, and a company statement of at least twelve months of funding, against $96.4 million of nine-month operating cash use and no at-the-market sales in 2026.

The negative case is equally documented. The FDA’s own reviewers wrote that the trial “did not meet its pre-specified primary and secondary efficacy endpoints” and found 0.66 points, p=0.24, on the plan they treat as pre-specified. Even on the company’s analysis, the effect that survives is 1.2 points of absolute change on a scale whose minimum detectable change in an individual patient has been put at 3.77 points by the scale’s developers. Every cardiac endpoint that supported the original application is now nominal only, because LVEF sat above them in the hierarchy and missed at p=0.09. The company withdrew a dated runway statement it had reaffirmed a quarter earlier, dropped its 2026 spending guidance, put its exosome platform and every non-lead programme on hold, slowed commercial preparation, and is in court trying to rescind the very agreement that would put the drug in front of patients — while that counterparty, its largest shareholder at about 8.5 per cent of the shares, claims breach of contract in arbitration for amounts that have not been disclosed. Not one insider bought a share this year; five directors put 442,826 shares under trading plans ten weeks before the vote; the executive chairman drew a 31.4 per cent withhold.

What the two cases have in common is that neither is settled by anything currently on the public record. The 24-month extension data presented in Hiroshima, around which the shares closed 10.50 per cent higher on September 30, reached the public record only in part: Capricor released the upper-limb analysis on October 5, in a company release and not in an SEC filing, and the shares were 33.7 per cent below their October 2 level on October 23, before recovering part of the decline by November 10. The third-quarter filings of November 10 add no 24-month figures. This is a market that has repriced on open-label, company-presented material the FDA has not yet ruled on, with short interest at about 36 per cent of the float at the September 30 and October 30 settlements against more than nine in ten retail messages bullish on October 4, into a date less than two weeks out.

Ownership into the decision. Two institutional filers reported no position at September 30, 2026 in amendments filed on November 13 and November 16: Tang Capital Management and the Montanova Capital and Averill Master Fund group, each at zero shares in its own Schedule 13G/A. Filings of this kind describe holdings at a stated date and can lag the decision they precede, so they are a reference point rather than a forecast of how the register will look after the FDA acts. Tang Capital amendment Montanova amendment

That is the honest shape of it: a single-asset company, on its third action date, on a narrowed indication, with a clean balance sheet, an unsettled commercial channel, a lease that resolves one way or the other by New Year’s Eve, two irreconcilable readings of the same pivotal trial, and, beyond the upper-limb analysis released on October 5, the numerical extension dataset still unpublished in any company release or filing as of November 10. Everything in this report is checkable against a dated source. The November outcome is not.

This report is informational and educational. It is not investment advice, not a recommendation to buy or sell any security, and not a solicitation. Nothing here is personalised to any reader’s circumstances. Figures are as filed or as of the stated date and may change. Readers should do their own research and consult a licensed financial adviser before any decision.

Merlintrader Health Score · CAPR

2.9out of 5
Balance sheet and runway · 30%3 / 5

About $198.5M at September 30, 2026 and a company statement of at least twelve months of funding, against $96.4M nine-month operating cash use and larger lease obligations.

Catalyst · 30%3 / 5

The November 22, 2026 target date, confirmed on November 10, and the December 31 lease contingency are concrete events with uncertain outcomes; a Form 483 response awaits FDA feedback.

Dilution · 20%2.5 / 5

No ATM sales in 2026 through November 10, but remaining financing capacity and equity awards stay relevant alongside a finite authorized share base.

Liquidity · 10%3.5 / 5

Exchange-reported short interest for the October 30, 2026 settlement shows a material short position of 18,765,089 shares and 7.38 days to cover.

Execution · 10%2 / 5

Statistical restatement, a one-observation Form 483, a 10% workforce reduction and partner proceedings weigh on the operating record.

Reassessed November 10, 2026 after the third-quarter results; scores unchanged from the October 26, 2026 assessment. The five weighted pillars total 2.85/5, displayed as 2.9 after rounding to one decimal. The score describes financial and operational robustness, not a valuation, price target or recommendation.

CAPR red flags

  • Binary FDA review risk and possible changes to the proposed label or timing.
  • A Form 483 with one observation from the July 2026 clinical-trial inspection; the company’s response was awaiting FDA feedback as of November 10, 2026.
  • Different statistical-plan interpretations and the restated cardiac endpoint.
  • Open-label extension comparisons are not concurrent randomized placebo comparisons.
  • Cash consumption, future financing and dilution.
  • Commercial-partner proceedings and approval-related lease obligations.
  • High dated short interest can amplify volatility without predicting direction.

CAPR Stock FAQ: Capricor Therapeutics Questions Answered

What is Capricor’s deramiocel PDUFA date?

Capricor’s August 24, 2026 announcement sets November 22, 2026 as deramiocel’s FDA target action date following a major amendment. The refined proposed indication focuses on upper-limb function in Duchenne muscular dystrophy. A target date does not guarantee approval, a particular label or an on-time decision. Details.

Is Capricor’s deramiocel FDA approved?

As of November 10, 2026, Capricor’s deramiocel remains under FDA review rather than approved, with the November 22 target date confirmed in the third-quarter release. The major amendment includes 24-month HOPE-3 open-label extension data and additional analyses supporting a refined proposed upper-limb indication in Duchenne muscular dystrophy. Details.

How much cash does Capricor have, and how long will it last?

Capricor reported about $198.5 million in cash, cash equivalents, restricted cash and marketable securities at September 30, 2026, against $96.428 million nine-month operating cash use, and says its resources are sufficient for at least the next twelve months. Spending, regulatory requirements and commercialization plans affect future funding needs. Details.

Is CAPR stock at risk of dilution?

Yes: Capricor’s September 30, 2026 quarterly filing describes an at-the-market program and equity awards, while outstanding common shares were 58,142,114 at November 9. The company sold no ATM shares from January 1 through November 10, 2026, but further capital raising or award exercises can dilute existing holders; that dated count is not a current fully diluted share total. Details.

When does Capricor report earnings?

Capricor released results for the third quarter ended September 30, 2026 after the market close on Tuesday, November 10, 2026, and management hosted a conference call and webcast at 4:30 p.m. ET that day. As of November 10, 2026, the company had not announced the date of its next quarterly report. The November 22 deramiocel target action date is a regulatory milestone, separate from the earnings schedule. Details.

What does Capricor Therapeutics do?

Capricor Therapeutics develops cell and exosome-based therapies. Its lead candidate, the cell therapy deramiocel for Duchenne muscular dystrophy, is under FDA review with a November 22, 2026 target action date, while its exosome-based programs are at an earlier stage of development. Details.

What did the FDA advisory committee vote mean for Capricor?

The July 29, 2026 advisory vote concerned deramiocel’s effectiveness in DMD cardiomyopathy, with nine votes against and three in favor. It was non-binding and preceded Capricor’s refined upper-limb amendment; the two proposed indications and their evidence must be distinguished. Details. Supporting document.

Does Capricor’s 76% HOPE-3 extension figure compare against placebo?

No: Capricor’s October 5, 2026 extension announcement compares the delayed-start group’s treated year with its own prior placebo year. There was no concurrent placebo arm in that comparison, so the 76% figure differs from a randomized concurrent treatment-versus-placebo result. Details.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CAPR or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms and conditions pages.